Alternative medicine: a big drug maker moves to play down mass-market pills

Article Abstract:

Unlike some of its competitors, Swiss pharmaceutical firm Roche Holding Ltd. is choosing to focus on the development of high cost drugs that are marketed primarily to specialty doctors instead of the mass market products that are often seen as sure money-makers. The low marketing budgets required for specialty drugs and the better odds of such products being picked up by cash-strapped governments and employers, are two reasons behind the company's strategy.

United States, Product development, Switzerland, Management dynamics, Executive changes & profiles, Drugs, Alliances, partnerships, Licensing/Sales Agreements, Management, Officials and employees, Biotechnology industry, Biotechnology industries, Licensing agreements, Company licensing agreement, Company business management, Roche Holding Ltd., Cooperative agreement for product development, Alliances and partnerships, Humer, Franz, Trimeris Inc.

---

Sequel for Vioxx critic: attack on diabetes pill; Glaxo shares plunge as Dr. Nissen sees risk to heart from Avandia

Article Abstract:

U.K.-based pharmaceutical company GlaxoSmithKline PLC shares dropped by 7% after analysis by Cleveland Clinic cardiologist Steven Nissen suggested a potential cardiovascular risk in patients taking Glaxo's antidiabetic drug Avandia. Avandia sales totaled $3 bil in 2006.

Sales, profits & dividends, Securities issued, listed, United Kingdom, Complications and side effects, Securities, Company sales and earnings, Company earnings/profit, Company securities, Avandia (Medication), GlaxoSmithKline PLC

---

Similar abstracts:

• Abstracts: Patent Medicine: push to develop new drugs sparks royalty rumbles. Schering-Plough to borrow to meet cash-flow needs
• Abstracts: Black comedy. Taking anger out of politics. Hidden weakness
• Abstracts: No prospectus? NYSE blames brokerage firms. Street's top dogs get top dollar. O'Neal crafts nimbler Merrill Lynch
• Abstracts: EU may allow drug marketing to patients. Sanofi weight-loss drug gains support in Europe
• Abstracts: P&G unveils big restructuring, including shift in its top spot. Motorola rises 9.2% following resignation of chairman, CEO

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.